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MaOBJECTIVES The present study sought to establish the dosage of intracoronary (IC) adenosine associated with minimal
side effects and above which no further increase in ﬂow can be expected.
BACKGROUND Despite the widespread adoption of IC adenosine in clinical practice, no wide-ranging, dose-response
study has been conducted. A recurring debate still exists regarding its optimal dose.
METHODS In 30 patients, Doppler-derived ﬂow velocity measurements were obtained in 10 right coronary arteries
(RCAs) and 20 left coronary arteries (LCAs) free of stenoses>20% in diameter. Flow velocity wasmeasured at baseline and
after 8ml bolus administrations of arterial blood, saline, contrast medium, and 9 escalating doses of adenosine (4 to 500 mg).
The hyperemic value was expressed in percent of the maximum ﬂow velocity reached in a given artery (Q/Qmax, %).
RESULTS Q/Qmax did not increase signiﬁcantly beyond dosages of 60 mg for the RCA and 160 mg for LCA. Heart rate did
not change, whereas mean arterial blood pressure decreased by a maximum of 7% (p < 0.05) after bolus injections of IC
adenosine. The incidence of transient A-V blocks was 40% after injection of 100 mg in the RCA and was 15% after in-
jection of 200 mg in the LCA. The duration of the plateau reached 12 13 s after injection of 100 mg in the RCA and 21 6 s
after the injection of 200 mg in the LCA. A progressive prolongation of the time needed to return to baseline was observed.
Hyperemic response after injection of 8 ml of contrast medium reached 65  36% of that achieved after injection of
200 mg of adenosine.
CONCLUSIONS This wide-ranging, dose-response study indicates that an IC adenosine bolus injection of 100 mg in the
RCA and 200 mg in the LCA induces maximum hyperemia while being associated with minimal side effects.
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AB BR E V I A T I O N S
AND ACRONYM S
AV = atrioventricular
FFR = fractional ﬂow reserve
IC = intracoronary
IV = intravenous
LCA = left coronary artery
= right coronary artery
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 1 , 2 0 1 5 Adjedj et al.
S E P T E M B E R 2 0 1 5 : 1 4 2 2 – 3 0 Intracoronary Adenosine Dose–Response Relationship
1423with papaverine. Due to its safe and sustained hy-
peremia, IV adenosine was used exclusively in the
landmark FAME (FFR versus Angiography for Multi-
vessel Evaluation) trial (5).
However, for a variety of reasons, IC adenosine has
been used more commonly in daily practice and in the
clinical published data (10). Despite this widespread
adoption of IC adenosine, a recurring debate still ex-
ists regarding its optimal dose. Therefore, our study
sought to deﬁne the dose–response relationship be-
tween IC adenosine and its resulting hyperemia.
METHODS
STUDY POPULATION. Patients with stable coronary
artery disease undergoing routine diagnostic coro-
nary angiography for a variety of indications were
approached for participation between April 2014 and
November 2014. All patients had documented coro-
nary atherosclerosis, but the measurements were
performed in vessels free of any stenosis with >20%
diameter reduction. Each subject provided written
informed consent as approved by the institutional
ethics committee.SEE PAGE 1431INTRACORONARY DOPPLER VELOCITY MEASUREMENT.
Following standard diagnostic coronary angiography,
200 mg of intracoronary nitroglycerin was adminis-
tered to minimize epicardial vasomotor tone. Then a
0.014-inch Doppler wire (FloWire, Volcano Corpora-
tion, San Diego, California) was introduced via a 6-F
guiding catheter into the target coronary artery and
was positioned under ﬂuoroscopy to obtain an
optimal and stable ﬂow velocity signal. In all patients,
the guidewire was manipulated to place the Doppler
sensor facing the oncoming coronary ﬂow.
First, resting Doppler velocity was measured and
recorded for at least 1 min to ensure a steady-state
baseline. Next, Doppler velocity was measured and
recorded for at least 1 min after an 8-ml IC bolus
administration of arterial blood, saline at room tem-
perature, contrast medium (iodixanol 270 mg/ml), 9
escalating doses of adenosine (4, 12, 20, 60, 100, 160,
200, 300, and 500 mg), and ﬁnally, a mixture of 200 mg
of adenosine plus contrast medium. For the sake of
this protocol, the adenosine solution prepared by the
pharmacy contained 100 mg/ml and the dilutions were
adjusted to reach 8 ml for all injections. To obtain
optimal ﬂow velocity tracings, we elected not to
ﬂush the “dead space.” This allowed the duration of
interruption of the aortic pressure signal to be mini-
mized (approximately 1.5 to 2 s). At the end of themeasurements performed after administra-
tion of contrast material, the remaining
contrast was removed from the catheter prior
to the next injection.
After each IC administration, no further
injection was performed for 2 min to allow
the Doppler velocity to return to its baseline
value. Heart rhythm and hemodynamic pa-
rameters of heart rate and mean aortic pres-
sure were recorded for each Doppler velocity
measurement.
Figure 1 depicts a typical Doppler velocity tracing
and indicates the indexes measured for each IC bolus.
We deﬁned the plateau hyperemic period as the time
during which ﬂow velocity reached at least 95% of its
maximum. The time needed to come back to baseline
was deﬁned by the return to <10% above the starting
value.
MODEL FOR FFR DEPENDENCE ON ADENOSINE
DOSE. To translate the IC adenosine dose into its
effect on FFR, a model based on standard coronary
physiology linked the degree of hyperemia to the
relative distal coronary pressure (Pd/Pa). It started
with the classic pressure loss versus ﬂow relationship
for a vascular stenosis (11):
DP ¼ Pa  Pd ¼ Cv  Q þ Ce  Q2
then transformed it into a more portable, unitless
form:
Pd=Pa ¼ 1  ðCv  Qr=PaÞ  ðQ=QrÞ
 Ce  Q2r

Pa
  ðQ=QrÞ2
where Cv and Ce are the viscous and expansion co-
efﬁcients that depend on vessel and stenosis geom-
etry, Pd is the distal coronary pressure, Pa is the
proximal coronary pressure, Qr is the resting ﬂow,
and Q is the current ﬂow. At rest, Q/Qr ¼ 1 and Pd/Pa is
termed rest Pd/Pa; at maximum hyperemia, Q/Qr is
termed the coronary ﬂow reserve (CFR) and Pd/Pa ¼
FFR.
The speciﬁc values chosen for rest Pd/Pa ¼ 0.93
and FFR ¼ 0.79 were based on the median values
from 1,593 lesions assessed by pressure wire (12), and
CFR ¼ 2.0 was based on the weighted average from
1,118 lesions assessed by Doppler wire (13). Using
these values in the model yielded a relationship be-
tween Pd/Pa and percentage of maximum hyperemia
starting at 0% (rest, Q/Qr ¼ 1) and ending at 100%
(hyperemia, Q/Qr ¼ CFR).
STATISTICAL ANALYSIS. Analyses were performed
using Prism GraphPad version 5.0 (GraphPad Soft-
ware, San Diego, California) and R version 3.1.2
(R Foundation for Statistical Computing, Vienna,
RCA
FIGURE 1 Example of a Typical Doppler Velocity Tracing and Illustration of the Various Measurements Performed in the Present Study
See text of the Methods section for the deﬁnition of these measurements. IC ¼ intracoronary.
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1424Austria) with standard summary statistics. Applicable
tests were 2-tailed, and p < 0.05 was considered
statistically signiﬁcant.
An analysis of variance (ANOVA) model with mixed
effects (to account for repeated measurements from
the same subject) tested for a signiﬁcant interaction
between contrast and adenosine in their 2-by-2
factorial design (baseline, contrast, 200 mg adenosine,
and both together). Similarly, an ANOVA mixed-
effects model compared Doppler velocity among the
3 viscosity conditions (saline, contrast, and blood).
If an overall ANOVA p value was signiﬁcant, then a
Tukey all-pair comparison was applied to determine
which conditions provided a different response.
Dose-response analysis was performed in 2 ways
(14). First, an ANOVA mixed-effects model with po-
tential Tukey all-pair comparison analyzed the ﬂow
response over 10 conditions (baseline plus 4, 12, 20,
60, 100, 160, 200, 300, and 500 mg IC adenosine).
Flow response was assessed by the normalized ﬂow, a
unitless ratio Q/Qmax, where Q equals the Doppler
velocity and Qmax represents the largest observed
Doppler velocity in response to IC adenosine. Hemo-
dynamic response assessed both heart rate and mean
arterial pressure.
Second, a model-based approach used an explicit
formula for the relationship between IC adenosine
dose and normalized ﬂow (Q/Qmax). Because adeno-
sine follows an enzymatic reaction to produce hy-
peremia, it makes physiological sense to employ the
Michaelis-Menten model for enzyme kinetics (14).
Two minor modiﬁcations were necessary to cus-
tomize the general model for the speciﬁcs of IC
adenosine hyperemia. Because Q/Qmax approaches a
maximum value of 1 at high/inﬁnite adenosine con-
centration and equals >0 at baseline due toendogenous adenosine in the coronary circulation,
our customized model was
Q=Qmax ¼ ðdose þ offsetÞ=ðk þ ½dose þ offsetÞ
where the constant “k” describes when Q/Qmax ¼ 50%
and the constant “offset” adjusts for baseline, phys-
iological adenosine. The variable “dose” equals the IC
adenosine amount in mg. The R package lme4 was
used for nonlinear ﬁtting of the model to the data.
Because a mixed effects model (to account for
repeated measurements from the same subject) pro-
duced similar results to a ﬁxed effects model (not
accounting for repeated measurements from the same
subject), results and ﬁgures employ the ﬁxed effects
model given more robust and accepted techniques for
its conﬁdence intervals.RESULTS
The characteristics of the 30 subjects are summa-
rized in Table 1. One subject received only 3 doses of
IC adenosine (4, 12, and 20 mg), and was excluded
from the ANOVA dose-response analysis but in-
cluded in all other analyses. Although all vessels
were free of any visible stenosis, the CFR varied from
1.42 to 4.88. The baseline ﬂow velocity was higher
in patients with a low CFR than in patients with a
high CFR. (29  11 cm/s vs. 16  7 cm/s; p < 0.001).
Hyperemic ﬂow velocity was similar in both groups
(61  26 cm/s vs. 55  17 cm/s; p ¼ NS).
DOSE-RESPONSE ANALYSIS. Figure 2 summarizes
the dose–response relationships and also displays
the incidence of high-grade atrioventricular (AV)
block for each dose of IC adenosine. One subject
received only 20 mg because the quality of the ﬂow
TABLE 1 Patient Characteristics and Medications (n ¼ 30)
Patient demographics
Age, yrs 65  11
Male 26 (87)
Body weight, kg 77  15
Height, cm 171  9
Hypertension 17 (59)
Hypercholesterolemia 18 (62)
Diabetes mellitus 4 (14)
Smoking 7 (24)
Prior PCI 10 (34)
Prior myocardial infarction 1 (3)
Medications
Aspirin 24 (80)
Clopidogrel 9 (30)
Ticagrelor 6 (20)
Statin 23 (77)
Beta-blockers 10 (33)
Calcium-channel inhibitors 8 (27)
Angiotensin-converting enzyme inhibitors 10 (33)
Angiotensin II receptor blocker 6 (20)
Nitroglycerin 1 (3)
Oral antidiabetic drugs 1 (3)
Insulin 3 (10%)
Values are mean  SD or n (%).
PCI ¼ percutaneous coronary intervention.
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1425velocity signal deteriorated and could not be
restored. All episodes of AV block were transient,
and none required speciﬁc treatment. However, ep-
isodes of transient AV block occurred at doses higher
than 100 mg, precluding the administration of higher
amounts than 300 mg of IC adenosine in 5 (17%)
patients.
Signiﬁcant differences in normalized ﬂow velocity
(Q/Qmax) existed via mixed effects ANOVA analysis
for all vessels together and for the right coronary
artery (RCA) and left coronary artery (LCA) sepa-
rately (p < 0.001 for all). Table 2 displays the
p values from the subsequent Tukey paired com-
parisons on a per-vessel basis. For the RCA, Q/Qmax
did not increase signiﬁcantly at any higher dose than
60 mg. For the LCA and all vessels together, Q/Qmax
did not increase signiﬁcantly at any higher dose than
160 mg.
Figure 3 shows the mean duration of plateau hy-
peremia, the time needed to return to baseline, as
well as the effect on heart rate and blood pressure.
For a bolus of 100 mg in the RCA, plateau hyperemia
lasted 12  13 s. For a bolus of 200 mg in the LCA,
plateau hyperemia lasted 21  6 s. The time needed
for the ﬂow velocity to return to baseline increased
progressively with the IC adenosine dose. In 10% of
patients, the ﬂow velocity did not return to base-
line within 2 min after at least 1 IC adenosineadministration. Although there was no signiﬁcant
change in heart rate among doses of IC adenosine
(ANOVA p ¼ 0.48), mean arterial pressure was altered
(ANOVA p ¼ 0.001). Tukey all-pair comparison of
mean arterial pressure showed signiﬁcant decreases
with all doses of IC adenosine compared with baseline
conditions (all p < 0.05) except for 4 mg (p ¼ 0.24), but
not between adenosine doses (all p > 0.60). Mean
arterial pressure decreased with IC adenosine by
about 6% to 7% from baseline on the basis of the
mixed effects model.
EFFECT OF BLOOD, SALINE, AND CONTRAST MEDIUM.
Doppler ﬂow velocity varied among 8-ml IC boluses
of arterial blood, saline, and contrast (p < 0.001 by
ANOVA), and all pairwise comparisons were signi-
ﬁcant (p < 0.001 for blood and contrast; p ¼ 0.041
for saline and blood; and p ¼ 0.013 for saline and
contrast). As shown in Figure 4, contrast increased
Doppler ﬂow velocity the most (þ38  52% over
blood, p < 0.001 by paired t test; þ17  28% over
saline, p ¼ 0.019) and saline was superior to blood
(þ21  43%, p ¼ 0.008). Flow velocity after contrast
medium reached 65  36% of the value reached after
200 mg of adenosine. Heart rate and mean arterial
pressure did not change signiﬁcantly after adminis-
tration of arterial blood, saline, or contrast (p ¼ 0.19
for pressure and p ¼ 0.37 for heart rate by ANOVA).
An 8-ml bolus injection of 200 mg adenosine mixed
with contrast medium showed no hyperemic syn-
ergy, nor did it prolong hyperemia (p ¼ 0.14 for
interaction term in ANOVA model).
DOSE-RESPONSE MODEL AND EFFECT ON FFR.
Figure 5 (left panel) shows both the raw Q/Qmax data
and the best-ﬁt models for each artery. Greater ﬂow
increases were observed in the RCA than the LCA for
the same IC adenosine dose. No important differences
existed between model parameters from a ﬁxed ef-
fects model (RCA k ¼ 2.84 mg, 95% conﬁdence interval
[CI]: 2.05 to 3.93, and offset ¼ 2.21 mg, 95% CI: 1.40 to
3.56; LCA k ¼ 3.95 mg, 95% CI: 3.33 to 4.68, and
offset ¼ 2.46 mg, 95% CI: 1.89 to 3.22) and a mixed
effects model (RCA k ¼ 3.05 mg, 95% CI: 1.81 to
4.29, and offset ¼ 1.94 mg, 95% CI: 1.43 to 2.46; LCA
k ¼ 4.07 mg, 95% CI: 4.02 to 4.11, and offset ¼ 2.26 mg,
95% CI: 2.22 to 2.29). Based on these dose-response
models, IC adenosine reaches 80% of maximum hy-
peremia at 9 or 13 mg (RCA vs. LCA), 90% of maximum
hyperemia at 23 or 33 mg, 95% of maximum hyperemia
at 52 or 73 mg, and 99% of maximum hyperemia
at 279 or 388 mg. Figure 5 (right panel) combines
this dose–response relationship with a physiological
model linking ﬂow increase to the observed FFR. At
0% hyperemia (baseline conditions), Pd/Pa ¼ 0.93,
FIGURE 2 Intracoronary Adenosine Dose-Flow Relationship
(Top) Dose-response data for the right coronary artery (RCA) (left panel) and the left coronary artery (LCA) (right panel). The data are
expressed as the percent of maximum for each patient (Q/Qmax) at each dose of intracoronary (IC) adenosine. The error bars represent the 95%
conﬁdence intervals for each value. The p values from the subsequent Tukey paired comparisons are given in Table 2. (Bottom) The bars
represent the percent of patients in whom high-grade atrioventricular (AV) block occurred with that dose of adenosine. BL ¼ baseline.
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1426whereas at 100% hyperemia (maximum), FFR ¼ 0.79.
IC adenosine doses between 60 and 200 mg
provide an FFR within 0.01 of the value at 100%
hyperemia.
DISCUSSION
The present dose-response study of IC adenosine on
intracoronary Doppler ﬂow velocity suggests that the
optimal bolus to induce maximal hyperemia consis-
tently and safely is 60 to 100 mg for the RCA and 160
to 200 mg for the LCA. Although sequential doses
above 60 mg for the RCA and 160 mg for the LCA
showed no statistically signiﬁcant further increase in
ﬂow (Table 2), the entire dose–response continuum
(Figures 2 and 5) demonstrates a reduction in inter-
individual variability around 100 to 200 mg, respec-
tively. Additionally, an undeﬁned proportion of
adenosine can potentially spill into the aorta during
IC administration, further implying the need for a
safety margin. Notably, we observed an increased
incidence of AV block at high doses (Figure 2).The occurrence of a transient AV block creates an
artifact on the tracings. Albeit always transient, such
episodes of AV block are disruptive during a cathe-
terization procedure and might cloud the accuracy
of the measurements, thus arguing for modest yet
sufﬁcient doses. Therefore, our suggested dose of
100 mg for the RCA and 200 mg for the LCA balances
hyperemia versus side effects.
The present data conﬁrm that the administration of
the IC adenosine does not induce any discomfort in
patients or any clinically signiﬁcant changes in heart
rate, blood pressure, or ST-T segment (15). Even at low
doses (4 and 12 mg), a marked increase in ﬂow velocity
was observed in all patients, eliminating the possi-
bility of any “resistance to adenosine.” The plateau
phase of maximal hyperemia at suggested optimal
doses averaged for the RCA and the LCA is 12  13 s and
21  6 s, respectively, which is long enough to make
accurate measurements, but too short to perform pull
back recordings. The time to return to baseline was 38
 20 s for the RCA and 77  10 s for the LCA, after
administration of 100 and 200 mg, respectively. These
TABLE 2 Dose-Response Analysis for Q/Qmax Showing Pairwise p Values Comparing Various IC Adenosine Doses (From Baseline to 500 mg)
for the RCA and LCA
4 mg 12 mg 20 mg 60 mg 100 mg 160 mg 200 mg 300 mg 500 mg
RCA
Baseline <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
4 mg 0.74 0.041 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
12 mg 0.94 0.055 0.002 0.004 <0.001 <0.001 0.008
20 mg 0.71 0.13 0.19 0.019 0.001 0.15
60 mg 0.99 1.00 0.83 0.35 0.93
100 mg 1.00 1.00 0.93 1.00
160 mg 1.00 0.91 1.00
200 mg 1.00 1.00
300 mg 1.00
LCA
Baseline <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
4 mg <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
12 mg 0.007 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
20 mg 0.23 0.010 <0.001 <0.001 <0.001 <0.001
60 mg 0.98 0.11 0.28 0.004 <0.001
100 mg 0.77 0.95 0.15 0.011
160 mg 1.00 0.99 0.68
200 mg 0.91 0.38
300 mg 1.00
Pairwise p values via analysis of variance then Tukey all-pair comparison.
IC ¼ intracoronary; LCA ¼ left coronary artery; Q/Qmax ¼ percentage of maximum ﬂow velocity; RCA ¼ right coronary artery.
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1427durations of action permit reliable yet quickly
repeated measurements. Akin for FFR measurements,
we did not ﬂush the dead space to avoid the “ﬂush
artifact” on the aortic pressure tracings. This implies
that the actual dosage of adenosine reaching the cor-
onary ostium is approximately 15% lower than the
amount leaving the syringe.
Because of the relatively short-lasting action of IC
adenosine, we recommend, in case of FFR measure-
ments, to record at least 10 beats at rest, followed by a
short lasting bolus injection, immediate reconnection
of the aortic pressure signal, and a total duration of
the recording of 60 s. This recording should then be
repeated in the exact same manner and stored. This
standardization of the recordings is important to
allow for their interpretation and review. With
increasing dosages, we also observed a prolongation
of the time needed to return to baseline. At higher
dosages, coronary blood ﬂow velocity did not return
to baseline despite waiting for several minutes. It
may be speculated that repetitive episodes of hyper-
emia (and of ischemia) lead to an up-regulation of the
adenosine receptors or of other mediators involved in
the molecular pathways leading to microvascular
dilation. The maintenance of a higher ﬂow after
several episodes of hyperemia questions the value of
physiological lesion assessment at rest soon after
coronary intervention without induction of maximal
hyperemia.EFFECTS OF ADENOSINE ON FLOW VELOCITY
VERSUS ON FFR. Because of curvilinear relationships
between IC adenosine dose and Doppler ﬂow velocity
(Figure 2) and between the degree of maximum hy-
peremia and Pd/Pa as known from fundamental ste-
nosis physiology, the net effect produces clinically
similar FFR values for even modest doses of IC
adenosine, as will be detailed in this section.
Recent work has determined that the test/retest
repeatability of FFR has an SD of approximately 0.02
(16). Thus, FFR differences <0.02, as seen in Figure 5,
for adenosine doses above about 40 mg are smaller
than the variability of the measurement itself. Inter-
preting the dose-response curve from this perspec-
tive, changes in ﬂow response for IC adenosine doses
>40 mg are smaller than the intrinsic variability of the
FFR measurement. As such, although large studies
might show a statistically signiﬁcant difference in
FFR for higher doses of IC adenosine, test/retest
repeatability indicates that these differences are not
clinically signiﬁcant.
On a related point, earlier workmeasured FFR using
doses of IC adenosine in the 30 to 60 mg (left) and 20 to
30 mg (right) range (17). For example, the pivotal
DEFER (FFR-based DEFERal versus performance of
coronary angioplasty) trial employed IC adenosine in
42% of cases, delivering 20 mg (left) and 15 mg (right) (4).
Our current dose-response relationship in Figure 5
(left panel) clariﬁes that 15 mg achieves at least 80%
FIGURE 3 Effect Duration and Hemodynamic Effects of Increasing Dosages of Intracoronary Adenosine
Dose–response summary data for duration of hyperemic plateau (seconds), time needed to return to baseline ﬂow velocity value (seconds), systemic blood pressure
(mm Hg), and heart rate (beats/min). Data are given as average  SD for each dose of intracoronary (IC) adenosine.
FIGURE 4 Hyperemic Effects of Intracoronary Injection of
Arterial Blood, Saline and Contrast Medium as Compared
to Adenosine
Effect on coronary Doppler ﬂow velocity from the administration
of an 8-ml bolus of arterial blood at body temperature, saline at
room temperature, and contrast medium at room temperature.
Data are given as average  SD of the percentage of maximum
ﬂow velocity for each patient (Q/Qmax).
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1428and 35 mg at least 90% of maximum hyperemia. As
translated by Figure 5 (right panel), these levels of
hyperemia would result in typical FFR measurements
within 0.02 to 0.03 of higher doses. Correspondingly,
DEFER found average FFR values using IC adenosine
that were larger than but still within 0.02 of IV aden-
osine, albeit in distinct patients (IC vs. IV adenosine:
reference group 0.58 vs. 0.56; performance group
0.88 vs. 0.86; and deferral group 0.86 vs. 0.87, all not
statistically signiﬁcant) (4). In agreement with our
current ﬁndings, these small differences in FFR were
neither clinically nor statistically signiﬁcant in the
DEFER trial.
COMPARISON WITH EXISTING PUBLISHED DATA.
Although studies of IC adenosine doses and Doppler
ﬂow velocity exist in the published data, no prior
study has created such a detailed and extensive
dose-response curve in patients. The original work
applying adenosine to the human coronary circula-
tion recorded Doppler velocity response in 33 arteries
for a lower range of IC adenosine from 2 to 16 mg only,
using IC papaverine as the comparator (15). They
FIGURE 5 Dose-Response Model and its Effect on FFR
The left panel plots the Q/Qmax for each patient as solid dots with their best-ﬁt line (red for the LCA and blue for the RCA) as a function of the
IC dose on a logarithmic x-axis (baseline placed at 1 mg). Note that overlap occurs among points at high doses. The right panel translates the
dose-response curve into the observed fractional ﬂow reserve (FFR) as a function of adenosine dose (RCA or LCA) for a typical lesion. This
theoretical model shows that at 60 to 100 mg in the RCA and at 160 to 200 mg (colors match left panel), the observed FFR is within 0.01 of its
minimum value. In addition, at dosages above 23 mg, the observed FFR is within 0.02 of its minimal value. Abbreviations as in Figure 2.
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1429observed that 16 mg produced hyperemia within 10%
of papaverine in 90% of patients, consistent with our
ﬁndings of a large increase in ﬂow at even low doses
of IC adenosine but submaximal in some cases.
Notably, we systematically explored a much wider
range of IC adenosine from 4 to 500 mg.
A smaller study of 21 patients compared Doppler
velocity between 30 and 50 mg and found no differ-
ence in hyperemic effect (18). By distinction, we
systematically injected IC adenosine up to 500 mg and
employed a speciﬁc dose-response model in our
analysis. A larger study of 457 patients found a sig-
niﬁcant increase in Doppler ﬂow velocity, albeit be-
tween 2 modest doses of IC adenosine (average 24 mg
vs. 35 to 36 mg) (19).
EFFECT OF SALINE AND CONTRAST MEDIUM. Finally,
we found that IC injections of contrast medium and
saline increased Doppler ﬂow velocity, with con-
trast’s being more potent. Extensive prior work has
demonstrated the hyperemic effect of contrast me-
dium, but mainly used older agents different from
modern, low osmolality formulations. Whether cur-
rent contrast agents produce meaningful hyperemia
for FFR measurement remains the subject of
ongoing study (CONTRAST trial, NCT02184117). We
note only that our results imply that both saline and
contrast produce some degree of hyperemia, pre-
sumably partially via transient hypoxia fromreplacement of oxygenated blood and partially by
stimulating endothelial paracrine pathways.
STUDY LIMITATIONS. We did not measure FFR
simultaneously due to less robust technology for
continuous and combined pressure/ﬂow measure-
ments, but we instead used standard physiology to
relate changes in ﬂow to changes in pressure loss.
A number of additional limitations have to be taken
into account. Although our sample size was modest, it
was of comparable magnitude to prior dose-response
work using IC adenosine and Doppler sensors (15,18).
Although each patient served as his or her own con-
trol to generate a dose-response curve for IC adeno-
sine, we did not measure the Doppler ﬂow velocity
response to IV adenosine or IC papaverine. Yet,
several other studies have shown that IV and IC
adenosine provided similar degrees of hyperemia
(15,20,21). Additionally, we did not explore IC aden-
osine doses above 500 mg, although our results sug-
gest diminishing returns from such ultra-high levels.
Also, the scientiﬁc rigor of the study would have been
increased by a randomization of the various dosages
of adenosine. Finally, only “normal” arteries were
studied. Yet, the complete dose-response effect on
ﬂow can be investigated only in vessels with minimal
or no epicardial resistance. In “critical” stenoses,
when the microvascular resistance reserve is already
exhausted at rest to compensate for the high epicar-
dial resistance, the ﬂow cannot increase further.
PERSPECTIVES
WHAT IS KNOWN? Intracoronary adenosine is often
used to induce hyperemia, but there is a persistent
debate about its optimal dosage.
WHAT IS NEW? This dose-response study with
ﬂow measurements indicates that IC bolus injections
of adenosine of 100 mg in the RCA and 200 mg in the
LCA induce maximum hyperemia without affecting
systemic hemodynamics and with minimal side
effects.
WHAT IS NEXT? These ﬁndings should help to
standardize the measurements and recordings of
coronary physiologic indexes both in clinical practice
and in the setting of clinical trials.
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1430Therefore, an FFR model is suboptimal to investigate
the full range of effects of adenosine.
CONCLUSIONS
On the basis of the present dose-response study of IC
adenosine and Doppler ﬂow velocity, we recommend
dosages of 100 mg in the right coronary artery and
200 mg in the left coronary artery. These dosages do
not induce any signiﬁcant side effects, achieve >95%
of maximum hyperemia, and are clinically indistin-
guishable from higher dosages when applied for FFR
measurements.
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